

Supplemental data article: "A multimodal biomarker predicts dissemination of bronchial carcinoid". EMBP Reuling et al.

	TC (n/total)	%	AC (n/total)	%	Total (n/total)	%	P-value
Rb +	96/111	86.5%	56/59	94.9%	152/170	89.4%	0.09
P16 +	30/111	27.0%	22/59	37.3%	52/170	30.6%	0.17
OTP +	95/112	84.8%	45/59	76.3%	140/171	81.9%	0.17
CD44 +	97/111	87.4%	40/58	70.0%	137/169	81.1%	0.004
Ki-67 (mean/SD)	2 (3.0)	NA	4 (5.0)	NA	3 (3.8)	NA	0.06


Supplementary Table 3: amount of positive stainings between TC and AC.

	Totaal (n=55)	TC (n=17)	AC (n=38)	p-value
CD44 positive	42	10	32	0.08
CD44 negative	13	7	6	
Ki-67 <5%	43	8	35	0.000
Ki-67 ≥5%	12	9	3	
Metastases	6	1	5	0.65
No metastases	49	16	33	

Supplementary Table 4: Patients (n=55) with one of the prognostic unfavorable characteristics ("other-group") (negative CD44, Ki-67) in relation to TC and AC.

Antibody	Company name	Clone	Species	Reference number	Dilution	IHC Incubation time (min)	Detection method
CD044	Ventana	SP37	Rb	06364985001	RTU	32	Optiview
MIB 1	Dako	MIB1	Mo	M7240	1/50	32	Optiview
OTP	Sigma	polycl	Rb	HPA059342	1/50	64	Optiview
RB	BD biosciences	G3-245	Mo	554136	1/1000 in Dako reduc ab dil	32	Optiview
P16	Ventana	E6H4	Mo	06695248001	1/2	32	Optiview

Supplementary Table 5: Clones and conditions of immunohistochemical markers, IHC: immunohistochemistry.



Supplementary Figure 4: correlation between Ki-67 and mitotic count, $p=0.22$.